Affimed N.V. (AFMD): Stock Offering News

AFMD – Company commences an underwritten public offering of its common shares.


Key Facts Surrounding This News Item


  • AFMD had a POWR Rating of C (Neutral) coming into today.
  • AFMD was 18.52% above its 10-Day Moving Average coming into today.
  • AFMD was 42.33% above its 20-Day Moving Average coming into today.
  • AFMD was 53.80% above its 50-Day Moving Average coming into today.
  • AFMD was 31.07% above its 100-Day Moving Average coming into today.
  • AFMD was 19.63% above its 200-Day Moving Average coming into today.
  • AFMD had returned +84.62% year-to-date leading up to today’s news, versus a -2.01% return from the benchmark S&P 500 during the same period.

More Info About Affimed N.V. (AFMD)


Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company was founded in 2000 and is based in Heidelberg, Germany. View our full AFMD ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

AFMD at a Glance

AFMD Current POWR Rating™
Overall POWR Rating™
AFMD Current Price $2.05 6.82%
More AFMD Ratings, Data, and News

AFMD Price Reaction

The day of this event (Feb. 12, 2018)
AFMD Closing Price$2.45 2.08%
AFMD Volume819,000
128.62% from avg
Leading up to this event
AFMD 1-mo return84.62%
After this event
AFMD 1-day return17.07%
AFMD 3-day return9.09%
AFMD 5-day return17.07%

AFMD Price Chart



More Affimed N.V. (AFMD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AFMD News
Page generated in 0.9768 seconds.